Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine

Trial Profile

Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertussis acellular vaccine (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Pneumococcal 11-valent vaccine conjugate; RIX 4414
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Pharmacodynamics
  • Acronyms PA-TRICOMP005
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 06 Apr 2022 This trial has been completed in Netherland (End Date: 26 Aug 2012), according to European Clinical Trials Database record.
  • 28 Feb 2018 This trial has been discontinued in Belgium as per European Clinical Trials Database record.
  • 24 Feb 2011 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top